Do analysts prefer XOMA or XOMAO?

XOMA Royalty currently has a consensus price target of $53.75, suggesting a potential upside of 28.71%. Given XOMA Royalty's stronger consensus rating and higher possible upside, research analysts plainly believe XOMA Royalty is more favorable than XOMA. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XOMA Royalty 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14 XOMA 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, XOMA or XOMAO?

XOMA Royalty has higher revenue and earnings than XOMA. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XOMA Royalty $52.15M 10.04 $31.71M $1.57 26.60 XOMA $7.65M N/A N/A N/A N/A

Is XOMA or XOMAO more profitable?

XOMA Royalty has a net margin of 53.46% compared to XOMA's net margin of 0.00%. XOMA Royalty's return on equity of 12.56% beat XOMA's return on equity. Company Net Margins Return on Equity Return on Assets XOMA Royalty 53.46% 12.56% 4.11% XOMA N/A N/A N/A

Which has higher valuation and earnings, XOMA or NVAX?

Novavax has higher revenue and earnings than XOMA Royalty. Novavax is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XOMA Royalty $52.15M 10.04 $31.71M $1.57 26.60 Novavax $1.12B 1.25 $440.30M -$0.58 N/A

Is XOMA or NVAX more profitable?

XOMA Royalty has a net margin of 53.46% compared to Novavax's net margin of -14.73%. XOMA Royalty's return on equity of 12.56% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets XOMA Royalty 53.46% 12.56% 4.11% Novavax -14.73% -14.82% 1.23%

Does the media prefer XOMA or NVAX?

In the previous week, Novavax had 5 more articles in the media than XOMA Royalty. MarketBeat recorded 8 mentions for Novavax and 3 mentions for XOMA Royalty. XOMA Royalty's average media sentiment score of 0.94 beat Novavax's score of 0.30 indicating that XOMA Royalty is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XOMA Royalty 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, XOMA or INVA?

Innoviva has higher revenue and earnings than XOMA Royalty. Innoviva is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XOMA Royalty $52.15M 10.04 $31.71M $1.57 26.60 Innoviva $411.33M 4.13 $271.17M $6.01 3.83

Is XOMA or INVA more profitable?

Innoviva has a net margin of 119.89% compared to XOMA Royalty's net margin of 53.46%. Innoviva's return on equity of 33.33% beat XOMA Royalty's return on equity. Company Net Margins Return on Equity Return on Assets XOMA Royalty 53.46% 12.56% 4.11% Innoviva 119.89% 33.33% 22.67%

Does the media refer more to XOMA or INVA?

In the previous week, Innoviva had 1 more articles in the media than XOMA Royalty. MarketBeat recorded 4 mentions for Innoviva and 3 mentions for XOMA Royalty. XOMA Royalty's average media sentiment score of 0.94 beat Innoviva's score of 0.70 indicating that XOMA Royalty is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XOMA Royalty 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, XOMA or MNKD?

XOMA Royalty has higher earnings, but lower revenue than MannKind. MannKind is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XOMA Royalty $52.15M 10.04 $31.71M $1.57 26.60 MannKind $348.97M 3.21 $5.86M -$0.07 N/A

Is XOMA or MNKD more profitable?

XOMA Royalty has a net margin of 53.46% compared to MannKind's net margin of -6.63%. XOMA Royalty's return on equity of 12.56% beat MannKind's return on equity. Company Net Margins Return on Equity Return on Assets XOMA Royalty 53.46% 12.56% 4.11% MannKind -6.63% -11.21% -3.92%

Does the media prefer XOMA or MNKD?

In the previous week, MannKind had 7 more articles in the media than XOMA Royalty. MarketBeat recorded 10 mentions for MannKind and 3 mentions for XOMA Royalty. XOMA Royalty's average media sentiment score of 0.94 beat MannKind's score of 0.72 indicating that XOMA Royalty is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XOMA Royalty 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ZBIO or XOMA?

XOMA Royalty has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zenas BioPharma $10M 113.07 -$377.74M -$8.47 N/A XOMA Royalty $52.15M 10.04 $31.71M $1.57 26.60

Does the media favor ZBIO or XOMA?

In the previous week, XOMA Royalty had 1 more articles in the media than Zenas BioPharma. MarketBeat recorded 3 mentions for XOMA Royalty and 2 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.94 equaled XOMA Royalty'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XOMA Royalty 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

XOMA Royalty (XOMA) Competitors

$41.76 -0.19 (-0.45%)

Closing price 04:00 PM Eastern

Extended Trading

$41.78 +0.02 (+0.04%)

As of 04:10 PM Eastern

Compare

XOMA vs. XOMAO, NVAX, INVA, MNKD, and ZBIO

Should you buy XOMA Royalty stock or one of its competitors? MarketBeat compares XOMA Royalty with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XOMA Royalty include XOMA (XOMAO), Novavax (NVAX), Innoviva (INVA), MannKind (MNKD), and Zenas BioPharma (ZBIO). These companies are all part of the "medical" sector.

How does XOMA Royalty compare to XOMA?

XOMA Royalty (NASDAQ:XOMA) and XOMA (NASDAQ:XOMAO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

XOMA Royalty currently has a consensus price target of $53.75, suggesting a potential upside of 28.71%. Given XOMA Royalty's stronger consensus rating and higher possible upside, research analysts plainly believe XOMA Royalty is more favorable than XOMA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14
XOMA	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

XOMA Royalty has a net margin of 53.46% compared to XOMA's net margin of 0.00%. XOMA Royalty's return on equity of 12.56% beat XOMA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	53.46%	12.56%	4.11%
XOMA	N/A	N/A	N/A

XOMA Royalty has higher revenue and earnings than XOMA.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$52.15M	10.04	$31.71M	$1.57	26.60
XOMA	$7.65M	N/A	N/A	N/A	N/A

95.9% of XOMA Royalty shares are owned by institutional investors. 8.9% of XOMA Royalty shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, XOMA Royalty had 1 more articles in the media than XOMA. MarketBeat recorded 3 mentions for XOMA Royalty and 2 mentions for XOMA. XOMA Royalty's average media sentiment score of 0.94 beat XOMA's score of 0.43 indicating that XOMA Royalty is being referred to more favorably in the media.

Company	Overall Sentiment
XOMA Royalty	Positive
XOMA	Neutral

Summary

XOMA Royalty beats XOMA on 11 of the 11 factors compared between the two stocks.

How does XOMA Royalty compare to Novavax?

XOMA Royalty (NASDAQ:XOMA) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

XOMA Royalty has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Novavax has a beta of 2.45, meaning that its share price is 145% more volatile than the broader market.

Novavax has higher revenue and earnings than XOMA Royalty. Novavax is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$52.15M	10.04	$31.71M	$1.57	26.60
Novavax	$1.12B	1.25	$440.30M	-$0.58	N/A

In the previous week, Novavax had 5 more articles in the media than XOMA Royalty. MarketBeat recorded 8 mentions for Novavax and 3 mentions for XOMA Royalty. XOMA Royalty's average media sentiment score of 0.94 beat Novavax's score of 0.30 indicating that XOMA Royalty is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XOMA Royalty	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.9% of XOMA Royalty shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 8.9% of XOMA Royalty shares are owned by company insiders. Comparatively, 1.6% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

XOMA Royalty has a net margin of 53.46% compared to Novavax's net margin of -14.73%. XOMA Royalty's return on equity of 12.56% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	53.46%	12.56%	4.11%
Novavax	-14.73%	-14.82%	1.23%

XOMA Royalty currently has a consensus target price of $53.75, indicating a potential upside of 28.71%. Novavax has a consensus target price of $12.13, indicating a potential upside of 41.65%. Given Novavax's higher possible upside, analysts plainly believe Novavax is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

Summary

XOMA Royalty beats Novavax on 10 of the 16 factors compared between the two stocks.

How does XOMA Royalty compare to Innoviva?

XOMA Royalty (NASDAQ:XOMA) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Innoviva has higher revenue and earnings than XOMA Royalty. Innoviva is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$52.15M	10.04	$31.71M	$1.57	26.60
Innoviva	$411.33M	4.13	$271.17M	$6.01	3.83

XOMA Royalty presently has a consensus target price of $53.75, suggesting a potential upside of 28.71%. Innoviva has a consensus target price of $36.20, suggesting a potential upside of 57.39%. Given Innoviva's stronger consensus rating and higher probable upside, analysts clearly believe Innoviva is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Innoviva has a net margin of 119.89% compared to XOMA Royalty's net margin of 53.46%. Innoviva's return on equity of 33.33% beat XOMA Royalty's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	53.46%	12.56%	4.11%
Innoviva	119.89%	33.33%	22.67%

In the previous week, Innoviva had 1 more articles in the media than XOMA Royalty. MarketBeat recorded 4 mentions for Innoviva and 3 mentions for XOMA Royalty. XOMA Royalty's average media sentiment score of 0.94 beat Innoviva's score of 0.70 indicating that XOMA Royalty is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XOMA Royalty	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

XOMA Royalty has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Innoviva has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

95.9% of XOMA Royalty shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 8.9% of XOMA Royalty shares are held by company insiders. Comparatively, 2.0% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Innoviva beats XOMA Royalty on 11 of the 16 factors compared between the two stocks.

How does XOMA Royalty compare to MannKind?

XOMA Royalty (NASDAQ:XOMA) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

XOMA Royalty has a net margin of 53.46% compared to MannKind's net margin of -6.63%. XOMA Royalty's return on equity of 12.56% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	53.46%	12.56%	4.11%
MannKind	-6.63%	-11.21%	-3.92%

XOMA Royalty currently has a consensus target price of $53.75, indicating a potential upside of 28.71%. MannKind has a consensus target price of $8.97, indicating a potential upside of 147.07%. Given MannKind's stronger consensus rating and higher possible upside, analysts clearly believe MannKind is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

95.9% of XOMA Royalty shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 8.9% of XOMA Royalty shares are owned by company insiders. Comparatively, 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, MannKind had 7 more articles in the media than XOMA Royalty. MarketBeat recorded 10 mentions for MannKind and 3 mentions for XOMA Royalty. XOMA Royalty's average media sentiment score of 0.94 beat MannKind's score of 0.72 indicating that XOMA Royalty is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XOMA Royalty	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

XOMA Royalty has higher earnings, but lower revenue than MannKind. MannKind is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$52.15M	10.04	$31.71M	$1.57	26.60
MannKind	$348.97M	3.21	$5.86M	-$0.07	N/A

XOMA Royalty has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, MannKind has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Summary

XOMA Royalty beats MannKind on 10 of the 16 factors compared between the two stocks.

How does XOMA Royalty compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and XOMA Royalty (NASDAQ:XOMA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

95.9% of XOMA Royalty shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by company insiders. Comparatively, 8.9% of XOMA Royalty shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, XOMA Royalty had 1 more articles in the media than Zenas BioPharma. MarketBeat recorded 3 mentions for XOMA Royalty and 2 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.94 equaled XOMA Royalty'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XOMA Royalty	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

XOMA Royalty has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than XOMA Royalty, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	113.07	-$377.74M	-$8.47	N/A
XOMA Royalty	$52.15M	10.04	$31.71M	$1.57	26.60

Zenas BioPharma presently has a consensus price target of $44.29, indicating a potential upside of 147.27%. XOMA Royalty has a consensus price target of $53.75, indicating a potential upside of 28.71%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Zenas BioPharma is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
XOMA Royalty	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14

XOMA Royalty has a net margin of 53.46% compared to Zenas BioPharma's net margin of 0.00%. XOMA Royalty's return on equity of 12.56% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
XOMA Royalty	53.46%	12.56%	4.11%

Zenas BioPharma has a beta of -0.71, indicating that its share price is 171% less volatile than the broader market. Comparatively, XOMA Royalty has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Summary

XOMA Royalty beats Zenas BioPharma on 10 of the 15 factors compared between the two stocks.

Get XOMA Royalty News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XOMA vs. The Competition

Export

Metric	XOMA Royalty	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$526.10M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	26.60	18.83	24.65	23.63
Price / Sales	10.04	290.84	500.87	105.21
Price / Cash	73.58	120.20	43.05	54.72
Price / Book	6.17	8.00	10.43	6.70
Net Income	$31.71M	$23.89M	$3.56B	$337.26M
7 Day Performance	0.14%	-3.49%	-1.39%	-1.41%
1 Month Performance	-0.31%	1.03%	0.86%	1.15%
1 Year Performance	67.04%	34.39%	19.42%	22.61%

XOMA Royalty Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XOMA XOMA Royalty	2.5493 of 5 stars	$41.76 -0.5%	$53.75 +28.7%	+65.9%	$526.10M	$52.15M	26.60	10
XOMAO XOMA	N/A	$25.36 +0.1%	N/A	+0.3%	$0.00	$7.65M	N/A	10	Short Interest Increase
NVAX Novavax	1.8855 of 5 stars	$10.06 -8.3%	$12.13 +20.6%	+17.0%	$1.80B	$1.12B	N/A	1,990
INVA Innoviva	3.983 of 5 stars	$21.38 -0.2%	$36.20 +69.3%	+4.4%	$1.59B	$420.69M	3.61	100	High Trading Volume
MNKD MannKind	3.5448 of 5 stars	$3.52 -6.6%	$8.97 +154.6%	-18.3%	$1.16B	$348.97M	N/A	400	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XOMA) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XOMA Royalty (XOMA) Competitors

XOMA vs. XOMAO, NVAX, INVA, MNKD, and ZBIO

How does XOMA Royalty compare to XOMA?

Summary

How does XOMA Royalty compare to Novavax?

Summary

How does XOMA Royalty compare to Innoviva?

Summary

How does XOMA Royalty compare to MannKind?

Summary

How does XOMA Royalty compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XOMA vs. The Competition

XOMA Royalty Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XOMA Royalty (XOMA) Competitors

XOMA vs. XOMAO, NVAX, INVA, MNKD, and ZBIO

How does XOMA Royalty compare to XOMA?

Do analysts prefer XOMA or XOMAO?

Is XOMA or XOMAO more profitable?

Which has better valuation & earnings, XOMA or XOMAO?

Do institutionals and insiders hold more shares of XOMA or XOMAO?

Does the media prefer XOMA or XOMAO?

Summary

How does XOMA Royalty compare to Novavax?

Which has more volatility and risk, XOMA or NVAX?

Which has higher valuation and earnings, XOMA or NVAX?

Does the media prefer XOMA or NVAX?

Do institutionals & insiders believe in XOMA or NVAX?

Is XOMA or NVAX more profitable?

Do analysts prefer XOMA or NVAX?

Summary

How does XOMA Royalty compare to Innoviva?

Which has stronger valuation and earnings, XOMA or INVA?

Do analysts recommend XOMA or INVA?

Is XOMA or INVA more profitable?

Does the media refer more to XOMA or INVA?

Which has more risk & volatility, XOMA or INVA?

Do institutionals & insiders believe in XOMA or INVA?

Summary

How does XOMA Royalty compare to MannKind?

Is XOMA or MNKD more profitable?

Do analysts rate XOMA or MNKD?

Do insiders and institutionals believe in XOMA or MNKD?

Does the media prefer XOMA or MNKD?

Which has preferable earnings & valuation, XOMA or MNKD?

Which has more risk & volatility, XOMA or MNKD?

Summary

How does XOMA Royalty compare to Zenas BioPharma?

Do insiders and institutionals have more ownership in ZBIO or XOMA?

Does the media favor ZBIO or XOMA?

Which has higher valuation and earnings, ZBIO or XOMA?

Do analysts rate ZBIO or XOMA?

Is ZBIO or XOMA more profitable?

Which has more risk & volatility, ZBIO or XOMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XOMA vs. The Competition

XOMA Royalty Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools